Faeth Therapeutics has launched as a publicly traded oncology company focused on advancing PIKTOR, an investigational oral therapy targeting the PI3K/AKT/mTOR signalling pathway, following the completion of its transition from Sensei Biotherapeutics.

The company’s shares are expected to begin trading on Nasdaq under the ticker symbol FTH after shareholders approved the conversion of preferred stock issued as part of the acquisition of Faeth Therapeutics earlier this year. The move completes a broader strategic shift that included a concurrent private placement generating approximately $200 million in gross proceeds.

While the corporate name change marks the end of the company’s former identity, the more significant development is its sharpened focus on PIKTOR, a multi-node inhibitor designed to target PI3K-alpha, mTORC1 and mTORC2 through an all-oral regimen. The investigational therapy is being developed to address cancers driven by alterations in the PI3K/AKT/mTOR pathway, one of the most frequently dysregulated signalling pathways in oncology.

The company said topline Phase 2 data evaluating PIKTOR in advanced endometrial cancer remain on track for release during the second half of 2026. Interim Phase 1b/2 data in HR+/HER2- advanced breast cancer are expected in 2027.

anand parikh, chairman, president and chief executive officer, said: “Starting tomorrow, we will begin trading on Nasdaq under our new name and ticker as a well-capitalized public company backed by a syndicate of leading life sciences investors and focused on a clear set of clinical catalysts.”

He added: “For two decades, drugs that block a single node of the PI3K/AKT/mTOR pathway have been undone by the tumor’s ability to route around them. PIKTOR represents our answer to this challenge: an all-oral regimen that patients can take at home, designed to inhibit PI3K-alpha, mTORC1 and mTORC2 at once, close the routes tumors may use to escape, and potentially drive deeper, more durable suppression, with the potential for a best-in-class profile.”

The transition follows the February 2026 acquisition of Faeth Therapeutics by Sensei Biotherapeutics and the completion of a financing intended to support the company’s clinical development strategy. Shareholder approval for the conversion of the associated Series B preferred stock cleared one of the final steps in completing the transaction.

Alongside the rebrand, the company has appointed a new executive leadership team led by Parikh, a co-founder of Faeth. brian stephenson has been named chief financial officer, while oliver maddocks continues as chief scientific officer and debbie chirnomas serves as chief medical officer.

The board has also been expanded with the appointments of former FDA commissioner stephen hahn and life sciences adviser saira ramasastry.

The company believes its multi-node approach may overcome limitations associated with therapies that inhibit only a single component of the PI3K/AKT/mTOR pathway. Whether that strategy translates into improved patient outcomes will become clearer as clinical data emerge from the ongoing development programme, beginning with the anticipated Phase 2 readout later this year.